| __timestamp | BioMarin Pharmaceutical Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 13774000 |
| Thursday, January 1, 2015 | 402271000 | 22479000 |
| Friday, January 1, 2016 | 476593000 | 27388000 |
| Sunday, January 1, 2017 | 554336000 | 35610000 |
| Monday, January 1, 2018 | 604353000 | 49007000 |
| Tuesday, January 1, 2019 | 680924000 | 61139000 |
| Wednesday, January 1, 2020 | 737669000 | 68836000 |
| Friday, January 1, 2021 | 759375000 | 97592000 |
| Saturday, January 1, 2022 | 854009000 | 106903000 |
| Sunday, January 1, 2023 | 937300000 | 120998000 |
| Monday, January 1, 2024 | 1009025000 |
Unleashing the power of data
In the competitive world of biotechnology, managing expenses is crucial for sustained growth. Over the past decade, BioMarin Pharmaceutical Inc. and Vericel Corporation have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. BioMarin, a leader in the field, has seen its SG&A expenses grow by approximately 210% from 2014 to 2023, reflecting its expansive operations and market reach. In contrast, Vericel Corporation, while smaller, has demonstrated a remarkable 780% increase in the same period, indicating aggressive growth and investment in its capabilities. This divergence highlights the different strategies employed by these companies: BioMarin's steady expansion versus Vericel's rapid scaling. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into the operational strategies of leading firms.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
Gross Profit Analysis: Comparing BioMarin Pharmaceutical Inc. and Vericel Corporation
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited